News
Regeneron will have a tough job taking on AstraZeneca’s big-selling Ultomiris in the market for paroxysmal nocturnal haemoglobinuria (PNH) therapies – but new biomarker data suggests it could ...
Welcome to the Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Case Review, a series of case presentations by an expert in the field of PNH. In this video, Ilene C. Wetiz, MD, professor of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback